Close

move up move left move right move bottom

Dosing and Administration for Reducing Stroke Risk in Nonvalvular AF

Convenient once-daily dosing with the evening meal

For patients with nonvalvular atrial fibrillation (AF) at risk for stroke, XARELTO® offers once-daily dosing with the evening meal and no routine coagulation monitoring.1,2

Once-daily dosing taken with the evening meal, to reduce stroke risk in nonvalvular AF
Download Dosing Summary

Renal dosing considerations

  • Nonvalvular AF: Adjust XARELTO® dose based on renal function. Avoid using XARELTO® in patients with CrCl <15 mL/min. Periodically assess renal function as clinically indicated and adjust therapy. Discontinue XARELTO® in patients who develop acute renal failure

Please see full Prescribing Information for additional dosing considerations.

Temporary discontinuation for surgery and other procedures

If XARELTO® must be discontinued for a procedure, follow these guidelines:

Before procedure:

  • Stop XARELTO® at least 24 hours before the procedure

  • In deciding whether a procedure should be delayed until 24 hours after the last dose of XARELTO®, the increased risk of bleeding should be weighed against the urgency of intervention

After procedure:

  • Restart XARELTO® as soon as adequate hemostasis is established, noting that the time to onset of therapeutic effect is short

  • If oral medication cannot be taken during or after surgical procedures, consider a parenteral anticoagulant

Note that the half-life of XARELTO® is 5 to 9 hours in healthy subjects aged 20 to 45 years and 11 to 13 hours in the elderly.

Other administration options

For patients who are unable to swallow whole tablets:

  • Crush and mix a 15-mg or 20-mg XARELTO® tablet with applesauce immediately prior to use and administer orally

  • Immediately follow the 15-mg or 20-mg dose with food

For administration via NG tube or gastric feeding tube:

  • Confirm gastric placement of the tube, then crush a 15-mg or 20-mg XARELTO® tablet, suspend in 50 mL of water, and administer via an NG tube or gastric feeding tube

  • Avoid administering XARELTO® distal to the stomach, which can result in reduced absorption and, thereby, reduced drug exposure

  • Immediately follow the 15-mg or 20-mg dose with enteral feeding

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

References:

  1. Patel MR, Mahaffey KW, Garg J, et al; and the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
  2. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47(3):203-216.